Sudarshan Pharma shares surged nearly 4% to ₹20.25 after reporting Q3FY26 revenue of ₹158.37 crore, a 37% YoY increase. Net profit rose 56% to ₹43.05 crore. Despite a 27.40% drop in January, the stock shows a strong long-term gain of 165%.
Recent Posts
- Allocate 10–25% globally, use ETFs for diversification: Himanshu Kohli of Client Associates
- From geopolitics to crude oil: Deepak Jorwal highlights key risks investors must track in 2026
- Muthoot Finance among 6 F&O stocks with a sharp rise in futures open interest
- HPCL, BPCL, IOC shares in focus as oil eases from recent highs after Trump signals potential end to war
- Rs 12,000 crore magic pill race begins to shrink India’s pot bellies. Which pharma stocks will win GLP-1 war?